12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LY2780301: Phase I data

An open-label, dose-escalation, Spanish Phase I trial in 32 patients with advanced or metastatic cancer showed that 100-500 mg oral LY2780301 in 28-day cycles was well tolerated. Eli Lilly said the recommended Phase II dose will be in the 300-500...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >